« Return to News | Ethics/Regulatory

FDA approves Whooping Cough vaccine

Monday, July 11, 2011 12:24 PM

The FDA has approved GlaxoSmithKline’s BOOSTRIXR [Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap)] for use in adults 65 years of age and older for active booster immunization against tetanus, diphtheria and pertussis (whooping cough). This approval makes BOOSTRIX the first Tdap vaccine approved for use in this age group.

BOOSTRIX is now approved for use as a single dose in individuals 10 years of age and older—the broadest age range for any Tdap vaccine.

The approval of BOOSTRIX for use in adults 65 years of age and older was based on two clinical trials in which more than 1,100 U.S. subjects received BOOSTRIX

"Although many people may have been vaccinated against whooping cough as children, immunity can wear off over time.  Adults, including those aged 65 and older, should speak with their healthcare providers to make sure their vaccinations are up to date and to discuss the Centers for Disease Control and Prevention's (CDC) recommendations for preventing tetanus, diphtheria and pertussis,” said Leonard Friedland, GSK’s vice president, clinical and medical affairs for North America. 

Whooping cough is one of the most commonly occurring vaccine-preventable diseases in the U.S.

In 2010, California declared a whooping cough epidemic. Michigan, Ohio, New York and Pennsylvania also reported increases in cases in 2010 compared to 2009.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.